No Data
Pacific Securities: Q3 revenue and profit growth of the active pharmaceutical ingredient sector have accelerated significantly, bullish on the high growth trend in Q4 performance.
In Q1 2024, the sector's gross margin is 36.38%, with a net margin of 12.78%. Q2 gross margin is 37.21%, with a net margin of 15.52%. Q3 gross margin is 38.27%, +1.88pct year-on-year, +1.06pct quarter-on-quarter, and net margin is 14.07%, +3.98pct year-on-year, -1.45pct quarter-on-quarter. Both gross margin and net margin have reached a new high compared to the same period in the past three years.
Jointown Pharmaceutical (300966.SZ): Currently, the company's business operations have not yet involved the field of AI.
Gelonghui November 6th|Joint Pharma (300966.SZ) stated on the investor interaction platform that the company's business development has not yet involved the AI field, and will carefully consider it in the future.
Jointown Pharmaceutical (300966): Q3 revenue and performance meet market expectations, with large-scale capacity gradually put into operation.
On October 23, 2024, the company released the third quarter report of 2024. In 2024 Q1-3, the company achieved revenue of 0.365 billion yuan (YoY -5.10%), with a net income attributable to the parent company of -0.014 billion yuan.
Kyodo Pharmaceutical: Third quarter report 2024
Jointown Pharma (300966.SZ): The net loss in the third quarter was 9.0436 million yuan.
On October 23, GeLongHui announced the third quarter report for 2024, with operating revenue of 0.132 billion yuan, a year-on-year increase of 12.24%; net income attributable to shareholders of listed companies -9.0436 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses -9.8436 million yuan; basic earnings per share -0.08 yuan.
September 30 A-share Lightning Rod: Joint Pharmaceutical: Shareholders Dan Venture Capital, Zhang Xin intend to reduce their shareholding by a total of no more than 3%; China Energy Construction: 18.206 billion shares of restricted shares will be unlocked
Dan Venture Capital and Zhang Xin, shareholders of Joint Pharmaceutical, plan to collectively reduce their shareholdings by not more than 3%; Shareholders holding more than 5% of the shares of Anlian Ruishi and their concerted action parties plan to collectively reduce their shareholding by not more than 2.93%; Shareholders Chang Cheng and Junlian Chengyu of Health One Medical plan to collectively reduce their shareholdings by not more than 2%; China Energy Construction stated that 18.206 billion shares will be released from restricted sales on September 30; *Special Treat Yinjiang Company's stocks are subject to additional implementation of other risk warnings; Uncertainty remains in the equity transfer of Yonghui Superstores; *Special Treat Baili Company's stocks are subject to additional implementation of other risk warnings.
No Data
No Data